Pulmatrix, Inc.
PULM Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$1.48
KIRA · Stoqly’s AI analyst, in plain words
- Pulmatrix, Inc. lost $5.2M in fiscal 2025.
Market cap
$5.4M
P/E
—
Revenue
—
Net income
−$5.2M
Free cash flow
—
Operating margin
—
Pulmatrix, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$5.2M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Pulmatrix, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- Pulmatrix, Inc.
- CIK
- 0001574235
Pulmatrix, Inc. · PULM
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $5.2M | $6.1M | $7.3M | $7.8M | — |
| Revenue growth | −59.1% | 17.5% | 20.2% | 7.0% | — |
| Net interest income | $0.0M | $0.3M | $0.9M | $0.5M | — |
| Operating margin | −390.2% | −312.1% | −202.0% | −125.1% | — |
| Net income | −$20.2M | −$18.8M | −$14.1M | −$9.6M | −$5.2M |
| Net margin | −390.2% | −310.3% | −193.5% | −122.5% | — |
| Diluted EPS | −$8.63 | −$5.46 | −$3.87 | −$2.62 | −$1.41 |
| Cash | |||||
| Cash from operations | −$19.7M | −$19.4M | −$16.0M | −$10.7M | −$5.4M |
| Capital expenditure | $0.1M | $0.1M | $0.7M | $0.4M | — |
| Free cash flow | −$19.9M | −$19.4M | −$16.7M | −$11.1M | — |
| FCF margin | −384.4% | −320.2% | −228.3% | −142.4% | — |
| Share count change | 88.4% | 127,187.2% | −99.9% | 0.0% | 0.0% |
| Debt and strength | |||||
| Cash and short-term investments | $53.8M | $35.6M | $19.2M | $9.5M | $4.1M |
| Shareholders' equity | $47.4M | $31.1M | $18.0M | $8.9M | $3.8M |
| Current ratio | 12.3x | 7.6x | 5.3x | 10.7x | 12.6x |
| Returns and quality | |||||
| Return on equity | −57.2% | −48.0% | −57.5% | −71.0% | −80.9% |
| Return on tangible equity | −49.2% | −60.5% | −78.5% | −106.8% | −135.5% |
| Piotroski F-score | 3 | 1 | 3 | 2 | — |
| Altman Z'' | −6.4 | −16.3 | −26.1 | −88.7 | −228.3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Pulmatrix, Inc. · PULM
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.48 a share, the company is worth $5.4M.
Source: SEC EDGAR XBRL filings (CIK 0001574235). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.